Finding new drugs that target RNA modifications in cancer
A High-Throughput Screening Platform to Discover RNA Methylation Inhibitors
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-10894111
This study is exploring how a special change in RNA, called m6A methylation, influences cancer and is creating a new tool to measure this change in living cells, which could help find new treatments for cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10894111 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a specific chemical modification of RNA, known as m6A methylation, affects gene expression and cellular functions, particularly in cancer. The researchers are developing a new tool that can detect changes in m6A levels in living cells, which will allow for high-throughput screening of potential drugs that can inhibit this modification. By optimizing this detection system, they aim to create cellular tools that can be used in various applications related to cancer treatment and understanding RNA biology.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit altered m6A methylation patterns.
Not a fit: Patients with cancers that do not involve m6A methylation or those with non-cancerous conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new cancer therapies that specifically target RNA modifications, potentially improving treatment outcomes for patients.
How similar studies have performed: Other research has shown promising results in targeting RNA modifications in cancer, indicating that this approach has potential for success.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEYER, KATHRYN D — DUKE UNIVERSITY
- Study coordinator: MEYER, KATHRYN D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancer Genes, Cancer-Promoting Gene, Cancers